



Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of
malaria RDTs: Round 3 (2010-2011)

Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of
malaria RDTs: Round 3 (2010-2011)

WHO Library Cataloguing-in-Publication Data :

Malaria rapid diagnostic test performance results of WHO product testing of malaria RDTs: round 3 (2010-2011).

1.Malaria - diagnosis. 2.Antimalarials - therapeutic use. 3.Malaria - drug therapy. 4.Diagnostic tests, Routine. 5.Reagent kits, Diagnostic - utilization.. 6.Sensitivity and specificity. I.UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. II.Centers for Disease Control (U.S.). III.Foundation for Innovative New Diagnostics.

ISBN 978 92 4 150256 6

(NLM classification: WC 750)

Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2011

All rights reserved.

The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.

This information product is not for sale. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.

The designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, the authors or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders. Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by WHO, including TDR, the authors or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted.

WHO, including TDR, and the authors of this health information product make no warranties or representations regarding the content, presentation, appearance, completeness or accuracy in any medium and shall not be held liable for any damages whatsoever as a result of its use or application. WHO, including TDR, reserves the right to make updates and changes without notice and accepts no liability for any errors or omissions in this regard. Any alteration to the original content brought about by display or access through different media is not the responsibility of WHO, including TDR, or the authors. WHO, including TDR, and the authors accept no responsibility whatsoever for any inaccurate advice or information that is provided by sources reached via linkages or references to this health information product.

Layout: Bruno Duret

Printed in Malta

Contents

ACKNOWLEDGEMENTS	VIII
ABBREVIATIONS	X
1. SUMMARY PERFORMANCE OF MALARIA RDTs: WHO PRODUCT TESTING: ROUNDS 1-3	1
1.1. Introduction	1
1.2. The WHO Product Testing Programme	1
1.3. Results of the evaluation	2
1.4. Summary of outcomes	3
1.5. Use of these results	3
2. WHO MALARIA RDT PRODUCT TESTING: ROUND 3 EXECUTIVE SUMMARY	13
2.1. Introduction	13
2.2. The WHO Product Testing Programme	13
2.3. Results of the evaluation	13
2.4. Use of these results	14
3. BACKGROUND	15
4. OBJECTIVE	16
5. MATERIALS AND METHODS	17
5.1. Test selection	17
5.2. Outline of the Product Testing Protocol	17
5.3. Evaluation panels	19
5.4. RDT registration	20
5.5. Specimen panel registration	20
5.6. Test phases	20
5.7. Performing rapid tests	20
5.8. Interpretation of results	20
6. DATA MANAGEMENT	21
7. QUALITY ASSURANCE	22
8. ETHICAL CONSIDERATIONS	22
9. DATA ANALYSIS	23
9.1. Measures of parasite detection: panel detection score and positivity rates	23
9.2. False-positive results	23
9.2.1. Incorrect species identification	23
9.2.2. False-positives from <i>Plasmodium</i> -negative samples	23
9.3. Band intensity	23
9.4. Lot agreement	23
9.5. Invalid tests	23
9.6. Heat (thermal) stability	24
10. LABORATORY VERSUS FIELD-BASED MALARIA RDT EVALUATIONS	24

11. RESULTS	25
11.1. Summary	25
11.2. Phase 1 – <i>P. falciparum</i> culture panel	30
11.3. Phase 2 – Wild-type <i>P. falciparum</i> and <i>P. vivax</i> and <i>Plasmodium</i> spp. negative samples	31
11.3.1. <i>P. falciparum</i> detection	31
11.3.2. <i>P. vivax</i> detection	32
11.3.3. Combined detection of <i>P. falciparum</i> and <i>P. vivax</i>	33
11.3.4. <i>P. falciparum</i> and <i>P. vivax</i> positivity rate	33
11.3.5. Band intensity	34
11.3.6. False-positive rates	35
12. HEAT STABILITY	37
12.1. <i>P. falciparum</i> test lines	40
12.2. Pan-specific test lines	43
13. EASE OF USE DESCRIPTION	45
14. DISCUSSION OF KEY FINDINGS	49
14.1. Panel Detection Score (PDS) and its relationship to sensitivity	49
14.2. False-positive rate and specificity	50
14.3. Heat (thermal) stability	50
14.4. Ease of use description	51
14.5. Inter-lot variability	51
14.6. Target antigens and species	52
15. USING THESE RESULTS TO ENSURE QUALITY OF DIAGNOSIS IN THE FIELD	52
15.1. Beyond procurement	52
15.2. Lot testing	53
16. CONCLUSIONS	53
17. REFERENCES	54
ANNEXES	55
Annex 1: Characteristics of rapid malaria tests in Round 3	56
Annex 2: Malaria RDT guide to results interpretation	58
Annex 3: Phase 1 results	70
Annex 4: Phase 2 results	74
Annex 5a: Selection of an appropriate RDT	104
Annex 5b: RDT format review and ease of use assessment	105
Annex 6: Introducing RDT-based malaria diagnosis into national programmes	106

Reference to any company or product in this report, particularly in any of the figures or tables, does not in any way imply an endorsement, certification, warranty of fitness or recommendation by WHO of any company or product for any purpose, and does not imply preference over products of a similar nature that are not mentioned. WHO furthermore does not warrant that: (1) any list of companies or products is complete and/or error free; and/or that (2) any products listed are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with the national laws and regulations of any country, including but not limited to patent laws. Inclusion in this report does not furthermore imply any approval by WHO of the products in question (which is the sole prerogative of national authorities). Any lists of RDTs are not an exhaustive list of malaria RDTs. Such lists reflect those products which have been submitted for evaluation in Round 3 of the WHO Malaria RDT Product Testing Programme. The fact that certain products are not included in any list means that they have not or not yet been submitted for evaluation in the WHO Malaria RDT Product Testing Programme and does not indicate anything in respect of such products' performance. WHO will not accept any liability or responsibility whatsoever for any injury, death, loss, damage, or other prejudice of any kind that may arise as a result of or in connection with the procurement, distribution and use of any product whatsoever included in this report. This report may not be used by manufacturers and suppliers for commercial or promotional purposes.

FIGURES

- Figure S1: Malaria RDT performance in Phase 2 of Rounds 1–3 against wild-type (clinical) samples containing *P. falciparum* at low (200) and high (2000 or 5000) parasite densities (parasites/μl) and clean-negative samples
- Figure S2: Malaria RDT performance in Phase 2 of Rounds 1–3 against wild-type (clinical) samples containing *P. vivax* at low (200) and high (2000 or 5000) parasite densities (parasites/μl) and clean-negative samples
- Figure 1: Mode of action of antigen-detecting malaria RDTs
- Figure 2: Network of specimen collection, characterization and testing sites
- Figure 3: Malaria RDT Product Testing Overview
- Figure 4a: Origin of Phase 2 *P. falciparum* wild-type (clinical) samples
- Figure 4b: Origin of Phase 2 *P. vivax* wild-type (clinical) samples
- Figure 5: Testing procedure and calculation of 'panel detection score' and band intensity for Product A against a sample density of 200 parasites/μl
- Figure 6: Testing procedure and calculation of 'panel detection score' and band intensity for Product A against a sample density of 2000 parasites/μl
- Figure 7: Phase 1 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite densities (parasites/μl) according to target antigen type (HRP2 or pLDH)
- Figure 8: Phase 2 *P. falciparum* panel detection score of malaria RDTs at low (200) and high (2000) parasite density (parasites/μl) according to target antigen type (HRP2 or pLDH)
- Figure 9: Phase 2 *P. vivax* panel detection score of malaria RDTs at low (200) and high (2000) parasite densities (parasites/μl) according to target antigen type (aldolase, pLDH)
- Figure 10: Phase 2 *P. falciparum* panel detection score and positivity rate at 200 parasites/μl
- Figure 11: Phase 2 *P. vivax* panel detection score and positivity rate at 200 parasites/μl
- Figure 12: Phase 2 *P. falciparum* (*P. falciparum* test line) false-positive rate against clean-negative samples
- Figure 13: Phase 2 *Plasmodium* spp. (pan or *P. vivax* test line) false-positive rate against clean-negative samples
- Figure 14: Phase 2 *P. falciparum* false-positive rate versus *P. falciparum* panel detection score at low (200) parasite density (parasites/μl)
- Figure 15: Phase 2 *P. vivax* false-positive rate versus *P. vivax* panel detection score at low (200) parasite density (parasites/μl)
- Figure 16: Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 17: Heat stability of *P. falciparum*-specific test line of *P. falciparum*-only tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 18: Heat stability of *P. falciparum*-specific test line in combination tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 19: Heat stability of *P. falciparum* specific test line in combination tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 20: Heat stability of pan-line of pan-specific tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 21: Heat stability of pan-line of pan-specific tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 22: Heat stability of pan-line of combination tests against a low density *P. falciparum* sample (200 parasites/μl). Positivity rate at baseline, and after 60 days incubation
- Figure 23: Heat stability of pan-line of combination tests against a high density *P. falciparum* sample (2000 parasites/μl). Positivity rate at baseline, and after 60 days incubation.
- Figure A6.1: Example malaria RDT implementation budget

TABLES

Table S1:	Malaria RDT Phase 2 performance in Rounds 1-3 against wild-type (clinical) samples containing <i>P. falciparum</i> and <i>P. vivax</i> at low (200) and high (2000 or 5000) parasite densities (parasites/ μ l) and clean-negative samples
Table S2:	Malaria RDT Rounds 1-3 heat stability results on a cultured <i>P. falciparum</i> sample at low (200) and high (2000) parasite density (parasites/ μ l). Positivity rate at baseline, and after 60 days incubation at 35°C and 45°C
Table S3:	Product resubmissions: WHO Malaria RDT Product Testing (Rounds 1-3)
Table 1:	Manufacturers and products accepted into Round 3 of WHO Malaria RDT Product Testing Programme
Table 2:	Characteristics of <i>Plasmodium</i> spp. negative specimens
Table 3:	Summary Phase 1 performance of 50 malaria RDTs against 20 cultured <i>P. falciparum</i> lines at low (200) and high (2000) parasite densities (parasites/ μ l)
Table 4:	Summary Phase 2 performance of 50 malaria RDTs against wild-type (clinical) <i>P. falciparum</i> and <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/ μ l) and <i>Plasmodium</i> spp. negative samples
Table 5:	Heat stability testing results for 50 malaria RDTs on a cultured <i>P. falciparum</i> sample at low (200) and high (2000) parasite densities (parasites/ μ l). Positivity rate at baseline, and after 60 days incubation at 35°C and 45°C
Table 6:	Ease of use description of 50 malaria RDTs
Table A3.1:	Lot variability in positive results against <i>P. falciparum</i> culture samples at low (200) and high (2000 or 5000) parasite densities (parasites/ μ l)
Table A3.2:	Distribution of test band intensity scores (0-4) against Phase 1 <i>P. falciparum</i> cultured parasites at low (200) and high (2000) parasite densities (parasites/ μ l)
Table A4.1:	Lot variability in positive results against Phase 2 wild-type <i>P. falciparum</i> and <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/ μ l)
Table A4.2:	Distribution of test band intensity (0-4) scores against Phase 2 wild-type <i>P. falciparum</i> samples at low (200) and high (2000) parasite densities (parasites/ μ l)
Table A4.3:	Distribution of Pan/Pv test band intensity (0-4) scores for Phase 2 wild-type <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/ μ l)
Table A4.4:	Panel detection score of Phase 2 wild-type <i>P. falciparum</i> in low (200) and high (2000) parasite densities (parasites/ μ l) by continent
Table A4.5:	Phase 2 <i>P. falciparum</i> test line false-positive rates for wild-type <i>P. vivax</i> samples at low (200) and high (2000) parasite densities (parasites/ μ l)
Table A4.6:	Phase 2 Pan (or <i>P. vivax</i>) test line false-positive rate for non-Pf infection on wild-type <i>P. falciparum</i> samples

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28633

